Efavirenz

ARV U.S. Brand Name

Sustiva

ARV Abbreviation(s)

EFV

U.S. FDA Label

Efavirenz Labeling (Package Insert)

ARV Class

Nonnucleoside reverse transcriptase inhibitors

First U.S. Approval

September 17, 1998

U.S. Manufacturer

Bristol Myers Squibb

Formulations

Strength	Formulation	Image	Description	Boosted
600 mg	Film-Coated Tablets Hard-gel Capsules	X	oval orange tablet with "Sustive" imprinted	No
200 mg	Film-Coated Tablets Hard-gel Capsules	X	oval orange tablet with "Sustive" and "200 mg" imprinted	No
50 mg	Film-Coated Tablets Hard-gel Capsules	X	Yellow and white capsule with "Sustiva" and "50 mg" imprinted	No

Generic Available?

Yes

FDCs

Efavirenz / Emtricitabine / Tenofovir DF

Efavirenz / Lamivudine / Tenofovir DF

Displaying 1 - 100 of 171

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Lenacapavir Efavirenz	Red: Avoid combination	Do not coadminister: decreased levels of lenacapavir	Potential for loss of lenacapavir efficacy	AUC decreased 55%; Cmax decreased 36%	600 mg daily (fasted)	Not reported	Use alternative agents
Ritonavir EFV 1060	Green: Administer standard doses	Administer standard doses	Possible increased effects of both drugs	Ritonavir AUC increased 18%	600 mg daily	Efavirenz AUC increased 21%	No dose adjustment required for boosting doses of ritonavir
Darunavir EFV 909	Green: Administer standard doses	Administer standard doses		Cmax decrease 15%, AUC decrease 13%, Cmin decrease 31%	600 mg once daily	Cmax increase 15%, AUC increase 21%, Cmin increase 17%
Atazanavir EFV 791	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir (all values compared to atazanavir 400 mg daily) AUC decreased 21%, Cmax no significant change, Cmin decreased 59%	600 mg daily on days 7-20	Not reported	In ART-naive patients standard dose efavirenz may be used with atazanavir 400 mg boosted with ritonavir 100 mg once daily. Do not coadminister efavirenz plus ritonavir-boosted atazanavir in ART-experienced patients. Do not coadminister efavirenz with unboosted atazanavir.
Atazanavir EFV 790	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential loss of antiretroviral efficacy	Atazanavir AUC decreased 74%, Cmax decreased 59%, Cmin decreased 93%, half-life: decreased 27%	600 mg daily on days 7-20	No significant change	In ART-naive patients standard dose efavirenz may be used with atazanavir 400 mg boosted with ritonavir 100 mg once daily. Do not coadminister efavirenz plus ritonavir-boosted atazanavir in ART-experienced patients. Do not coadminister efavirenz with unboosted atazanavir.
Atazanavir EFV 789	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential for increased atazanavir adverse effects	Atazanavir AUC increased 241%, Cmax increased 124%, Cmin increased 671%, half-life: increased 79%	600 mg daily with ritonavir 200 mg on days 15-28	Not reported	In ART-naive patients standard dose efavirenz may be used with atazanavir 400 mg boosted with ritonavir 100 mg once daily. Do not coadminister efavirenz plus ritonavir-boosted atazanavir in ART-experienced patients. Do not coadminister efavirenz with unboosted atazanavir.
Atazanavir EFV 788	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of atazanavir	Potential for increased atazanavir adverse effects	Atazanavir (all values compared to atazanavir 400 mg daily) AUC increased 39% , Cmax no significant change, Cmin increased 48%	600 mg daily x days 7-20	Not reported	In ART-naive patients standard dose efavirenz may be used with atazanavir 400 mg boosted with ritonavir 100 mg once daily. Do not coadminister efavirenz plus ritonavir-boosted atazanavir in ART-experienced patients. Do not coadminister efavirenz with unboosted atazanavir.
Tenofovir disoproxil fumarate EFV 744	Green: Administer standard doses	Administer standard doses		No significant change	600 mg once daily	No significant change
Tenofovir alafenamide EFV 712	Green: Administer standard doses	Administer standard doses		Cmin decreased 22%, AUC decreased 14%	600 mg once daily	Not studied
Etravirine EFV 552	Red: Avoid combination	Do not coadminister: Reduced levels of etravirine					Avoid combination: combining two NNRTIs has not been shown beneficial; use alternate agents
Efavirenz CBZ 512	Orange: Minimal data to guide interaction		Decreased efavirenz and carbamazepine effects	Not studied (may decrease efavirenz levels)		Not studied (may decrease carbamazepine levels)	Use alternative agents. If coadministering, monitor carbamazepine levels and adjust as indicated. Monitor antiviral efficacy
Efavirenz Tacrolimus 511	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits when using this combination	decreased effects of immunosuppresant				if co administiring, monitor immunosuppressant efficacy
Efavirenz Sirolimus 510	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits when using this combination	decreased effects of immunosuppresant				if co administiring, monitor immunosuppressant efficacy
Efavirenz CsA 509	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits when using this combination	decreased effects of immunosuppresant				if co administiring, monitor immunosuppressant efficacy
Efavirenz CsA 508	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits when using this combination	decreased effects of immunosuppresant				if co administiring, monitor immunosuppressant efficacy
Efavirenz CsA 507	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits when using this combination	decreased effects of immunosuppresant				if co administiring, monitor immunosuppressant efficacy
Efavirenz CBZ 506	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Decreased efavirenz and carbamazepine effects	EFV auc decreased 36%, Cmax decreased 21%, Cmin decreased 47%	200 mg daily x 3 days, 200 mg BID x 3 days, 400 mg daily for 15 days		Use alternative agents. If coadministering, monitor carbamazepine levels and adjust as indicated. Monitor antiviral efficacy
Efavirenz CBZ 505	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Decreased efavirenz and carbamazepine effects	Not studied (may decrease efavirenz levels)	200 mg daily x 3 days, 200 mg BID x 3 days, 400 mg daily for 20 days.	Carbmazepine AUC decreased 27%, Cmin decreased 35%, Cmax decreased 20%	Use alternative agents. If coadministering, monitor carbamazepine levels and adjust as indicated. Monitor antiviral efficacy
Efavirenz CBZ 504	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Decreased efavirenz and carbamazepine effects	Not studied (may decrease efavirenz levels)	200 mg daily x 3 days, 200 mg BID x 3 days, 400 mg daily for 20 days.	Carbmazepine AUC decreased 27%, Cmin 35%, Cmax decreased 20%	Use alternative agents. If coadministering, monitor carbamazepine levels and adjust as indicated. Monitor antiviral efficacy
Efavirenz Midazolam 503	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased midazolam effects (eg, increased sedation, confusion, respiratory depression)	Not studied		Not studied (may increase midazolam levels)	Parenteral midazolam can be used with caution when given as a single dose in a monitored situation for procedural sedation. Chronic midazolam administration (oral or intravenous) should be avoided.
Efavirenz NVP 502	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Decreased efavirenz effects	Efavirenz AUC decreased 22%; Cmin decreased 36%	200 mg daily x 2 weeks, then 400 mg daily	No significant change	Monitor and adjust therapy as indicated; may consider increasing efavirenz to 800 mg daily
Efavirenz Warfarin 501	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased or decreased warfarin effects (altered INR, increased risk of bleeding or clotting)	Not studied		Not studied (may increase or decrease warfarin levels)	If coadministering monitor INR and adjust warfarin as indicated. Monitor for signs and symptons of bleeding.
Efavirenz Warfarin 500	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased or decreased warfarin effects (altered INR, increased risk of bleeding or clotting)	Not studied		Not studied (may increase or decrease warfarin levels)	If coadministering monitor INR and adjust warfarin as indicated. Monitor for signs and symptons of bleeding.
Efavirenz Warfarin 499	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased or decreased warfarin effects (altered INR, increased risk of bleeding or clotting)	Not studied		Not studied (may increase or decrease warfarin levels)	If coadministering monitor INR and adjust warfarin as indicated. Monitor for signs and symptons of bleeding.
Efavirenz Clarithromycin 498	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Risk of QT interval prolongation	No significant change	500 mg Q12H x 7 days	Clarithromycin AUC decreased 39%; Cmax decreased 26%;14-hydroxy clarithromycin AUC increased 34%; Cmax increased 49%	Dose adjustment not established. Monitor for antbiotic efficacy and / or consider using alternative agents
Efavirenz Clarithromycin 497	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Risk of QT interval prolongation	No significant change	500 mg Q12H x 7 days	Clarithromycin AUC decreased 39%; Cmax decreased 26%;14-hydroxy clarithromycin AUC increased 34%; Cmax increased 49%	Dose adjustment not established. Monitor for antbiotic efficacy and / or consider using alternative agents
Efavirenz Clarithromycin 496	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Risk of QT interval prolongation	No significant change	500 mg Q12H x 7 days	Clarithromycin AUC decreased 39%; Cmax decreased 26%;14-hydroxy clarithromycin AUC increased 34%; Cmax increased 49%	Dose adjustment not established. Monitor for antbiotic efficacy and / or consider using alternative agents
Efavirenz Bosentan 495	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential decreased Efavirenz effects; potential decreased bosentran effects				If coadministring, monitor bosentran efficacy and virologic response
Efavirenz Proguanil 494	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits			100 mg with 250 mg atovaquone x 1	Proguanil AUC decreased 43%; Cmax no significant change	Consider using alternative agents. If coadministering, dose adjustment not established
Efavirenz Proguanil 493	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential decreased antimalarial effects		300 mg x 1	Proguanil AUC increased 113%; Cmax increased 47%; Cycloguanil AUC decreased 38%; Cmax decreased 31%	Consider using alternative agents. If coadministering, dose adjustment not established
Efavirenz Posaconazole 492	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased posaconazole effects		400 mg BID x 10 and 20 days	Posaconazole AUC decreased 50%; Cmax decreased 45%	Consider using alternative agents. If coadministering, dose adjustment has not been established
Efavirenz Posaconazole 491	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased posaconazole effects	No significant change	400 mg BID for 10 and 20 days	Posaconazole AUC decreased 50%; Cmax decreased 45%	Consider using alternative agents. If coadministering, dose adjustment has not been established
Efavirenz Posaconazole 490	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased posaconazole effects	No significant change	400 mg BID	Posaconazole AUC decreased 50%; Cmax decreased 45%	Consider using alternative agents. If coadministering, dose adjustment has not been established
Efavirenz Phenobarbital 489	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased efavirenz effects			Not studied	Avoid combination and use alternative agents. If coadministering, monitor phenobarbital levels and adjust as indicated
Efavirenz Phenobarbital 488	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased efavirenz effects	Not studied (may decrease levels)		Not studied	Avoid combination and use alternative agents. If coadministering, monitor phenobarbital levels and adjust as indicated
Efavirenz Phenobarbital 487	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased efavirenz effects	Not studied (may decrease levels)		Not studied	Avoid combination and use alternative agents. If coadministering, monitor phenobarbital levels and adjust as indicated
Efavirenz Phenytoin 486	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased efavirenz and phenytoin effects	Not studied (may decrease efavirenz levels)		Not studied (may decrease phenytoin levels)	Avoid combination and use alternative agents. If coadministering, \monitor phenytoin levels and adjust as indicated
Efavirenz Phenytoin 485	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased efavirenz and phenytoin effects	Not studied (may decrease efavirenz levels)		Not studied (may decrease phenytoin levels)	Avoid combination and use alternative agents. If coadministering, \monitor phenytoin levels and adjust as indicated
Efavirenz Ticagrelor 484	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Possible decreased ticagrelor levels				Avoid combination and use alternative agents
Efavirenz Clopidogrel 483	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Possible decreased activation of clopidogrel				Avoid combination and use alternative agents
Efavirenz Triazolam 482	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Increased triazolam effects (eg, increased sedation, confusion, respiratory depression)	Not studied		Not studied (may increase triazolam levels)	Avoid combination and use alternative agents
Efavirenz Ketoconazole 481	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased ketoconazole effects			Not studied (may decrease ketoconazole levels)	Avoid combination and use alternative agents
Efavirenz Ketoconazole 480	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased ketoconazole effects	Not studied		Not studied (may decrease ketoconazole levels)	Avoid combination and use alternative agents
Efavirenz Ketoconazole 479	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased ketoconazole effects	Not studied		Not studied (may decrease ketoconazole levels)	Avoid combination and use alternative agents
Efavirenz Itraconazole 478	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased itraconazole effects		200 mg Q12H x 28 days	Itraconazole AUC decreased 39%; Cmax decreased 37%; Cmin decreased 44%; Hydroxyitraconazole AUC decreased 37%; Cmax decreased 35%; Cmin decreased 43%	Avoid combination and use alternative agents
Efavirenz Itraconazole 477	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased itraconazole effects		200 mg Q12H x 28 days	Itraconazole AUC decreased 39%; Cmax decreased 37%; Cmin decreased 44%; Hydroxyitraconazole AUC decreased 37%; Cmax decreased 35%; Cmin decreased 43%	Avoid combination and use alternative agents
Efavirenz Itraconazole 476	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Decreased itraconazole effects	No significant change	200 mg Q12H x 28 days	Itraconazole AUC decreased 39%; Cmax decreased 37%; Cmin decreased 44%; Hydroxyitraconazole AUC decreased 37%; Cmax decreased 35%; Cmin decreased 43%	Avoid combination and use alternative agents
Efavirenz Atovaquone 475	Orange: Minimal data to guide interaction	Consider using alternative agents	Potentially compromised antimalarial activity		250 mg with 100 mg proguanil x 1	Atovaquone AUC decreased 75%; Cmax decreased 44%. Proguanil AUC decreased 43%	If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy.
Efavirenz Atovaquone 474	Orange: Minimal data to guide interaction	Consider using alternative agents	Potentially compromised antimalarial activity		250 mg with 100 mg proguanil x 1	Atovaquone AUC decreased 75%; Cmax decreased 44%. Proguanil AUC decreased 43%	If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy.
Efavirenz Atovaquone 473	Orange: Minimal data to guide interaction	Consider using alternative agents	Potentially compromised antimalarial activity		250 mg with 100 mg proguanil x 1	Atovaquone AUC decreased 75%; Cmax decreased 44%. Proguanil AUC decreased 43%	If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy.
Efavirenz Artemether / Lumefantrine 472	Orange: Minimal data to guide interaction	Consider using alternative agents	Potentially compromised antimalarial activity		artemether 20mg / lumefantrine 120 mg 4 tablets / dose for 6 doses total in 3 days	Aremether AUC decreased 79%, Lumefantrine AUC decreased 30%-56%.	If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy.
Efavirenz Artemether / Lumefantrine 471	Orange: Minimal data to guide interaction	Consider using alternative agents	Potentially compromised antimalarial activity	EFV AUC decreased 17%	artemether 20mg / lumefantrine 120 mg 4 tablets / dose for 6 doses total in 3 days	Aremether AUC decreased 51%, Cmax decreased 21% Lumefantrine AUC decreased 21%.	If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy.
Efavirenz Artemether / Lumefantrine 470	Orange: Minimal data to guide interaction	Consider using alternative agents	Potentially compromised antimalarial activity		artemether 20mg / lumefantrine 120 mg 4 tablets / dose for 6 doses total in 3 days	Aremether AUC decreased 51%, Cmax decreased 21% Lumefantrine AUC decreased 21%	If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy.
Efavirenz Saquinavir 469	Red: Avoid combination	Minimal data to guide interaction, weigh risks and benefits of using this combination	Potential loss of antiviral efficacy		1200 mg every 8 hours for 10 days	AUC decreased 62%, Cmin decreased 56%, Cmax decreased %50	Use alternative agents
Efavirenz Saquinavir 468	Red: Avoid combination	Minimal data to guide interaction, weigh risks and benefits of using this combination	Potential loss of antiviral efficacy		1200 mg every 8 hours for 10 days	AUC decreased 62%, Cmin decreased 56%, Cmax decreased %50	Use alternative agents
Efavirenz SOF/VEL 467	Red: Avoid combination	Do not coadminister: Reduced levels of velpatasvir and voxilapervir	Reduced levels of velapatasvir and voxilaprevir			Velpatasvir Cmax decreased 37%; AUC decreased 43%; Cmin decreased 47%	Contraindicated. Use alternative agents.
Efavirenz SOF/VEL 466	Red: Avoid combination	Do not coadminister: Reduced levels of velpatasvir and voxilapervir	Reduced levels of velapatasvir and voxilaprevir			Velpatasvir Cmax decreased 37%; AUC decreased 43%; Cmin decreased 47%	Contraindicated. Use alternative agents.
Efavirenz SOF/VEL 465	Red: Avoid combination	Do not coadminister: Reduced levels of velpatasvir and voxilapervir	Reduced levels of velapatasvir and voxilaprevir			Velpatasvir Cmax decreased 37%; AUC decreased 43%; Cmin decreased 47%	Contraindicated. Use alternative agents.
Efavirenz SOF/VEL 464	Red: Avoid combination	Do not coadminister: Reduced levels of velpatasvir and voxilapervir	Reduced levels of velapatasvir		400 / 100 mg daily x 14 days	Velpatasvir AUC decreased 53%, Cmin 57%, Cmax decreased 47%. Sofobuvir Cmax increased 38%.	Contraindicated. Use alternative agents.
Efavirenz SOF/VEL 463	Red: Avoid combination	Do not coadminister: Reduced levels of velpatasvir and voxilapervir	Reduced levels of velapatasvir		400 / 100 mg daily x 14 days	Velpatasvir AUC decreased 53%, Cmin 57%, Cmax decreased 47%. Sofobuvir Cmax increased 38%.	Contraindicated. Use alternative agents.
Efavirenz SOF/VEL 462	Red: Avoid combination	Do not coadminister: Reduced levels of velpatasvir		Efavirenz Cmin decreased 19%; AUC decreased 15%; Cmax deceased 10%	400 mg / 100 mg for 14 days	Sofosbuvir Cmax increased 38%. Velpatasvir Cmax decreased 47%; AUC decreased 53%; Cmin decreased 57%	Contraindicated. Use alternative agents.
Efavirenz Ethinyl estradiol / Norethindrone acetate 461	Red: Avoid combination	Do not coadminister: Reduced levels of progestin		No significant change	Ethinyl estradiol 50 mcg x 1 dose	No significant change	Use alternative contraceptive method
Efavirenz Etonogestrel 460	Red: Avoid combination	Do not coadminister: Reduced levels of progestin	Decreased effects of etonogestrel				Use alternative contraceptive method
Efavirenz Etonogestrel 459	Red: Avoid combination	Do not coadminister: Reduced levels of progestin	Decreased effects of etonogestrel			Etonogestrel decreased 61%	Use alternative contraceptive method
Efavirenz Etonogestrel 458	Red: Avoid combination	Do not coadminister: Reduced levels of progestin	Decreased effects of etonogestrel			Etonogestrel decreased 61%	Use alternative contraceptive method
Efavirenz EE/NGM 457	Red: Avoid combination	Do not coadminister: Reduced levels of progestin	Decreased effects of ethinyl estradiol and norgestimate		0.035 mg ethinyl estradiol / 0.25 mg norgestimate x 14 days	Ethinyl estradiol: no significant change; Norgestromin AUC decreased 64%; Cmax decreased 46%; Cmin decreased 82%	Use alternative contraceptive method
Efavirenz EE/NGM 456	Red: Avoid combination	Do not coadminister: Reduced levels of progestin	Decreased effects of ethinyl estradiol and norgestimate		0.035 mg ethinyl estradiol / 0.25 mg norgestimate x 14 days	Ethinyl estradiol: no significant change; Norgestromin AUC decreased 64%; Cmax decreased 46%; Cmin decrased 82%	Use alternative contraceptive method
Efavirenz EE/NGM 455	Red: Avoid combination	Do not coadminister: Reduced levels of progestin	Decreased effects of ethinyl estradiol and norgestimate		0.025 mg ethinyl estradiol / 0.25 mg norgestimate	Ethinyl estradiol: no significant change; Norgestromin AUC decreased 64%; Cmax decreased 46%; Cmin decrased 82%	Use alternative contraceptive method
Efavirenz Pimavanserin 454	Red: Avoid combination	Do not coadminister: Reduced levels of pimavanserin	Decreased pimavanserin levels				Avoid combination and use alternative agents
Efavirenz G/P 453	Red: Avoid combination	Do not coadminister: Reduced levels of Pibrenatasvir / Glecaprevir	decreased pibrenatasvir / glecaprevir effects				Contraindicated. Use alternative agents.
Efavirenz Lumateperone 452	Red: Avoid combination	Do not coadminister: Reduced levels of lumateperon	Decreased Lumateperon levels				Avoid combination and use alternative agents
Efavirenz LNG 451	Red: Avoid combination	Do not coadminister: Reduced levels of levonorgestrel	Decreased levonorgestrel effects		0.75 mg x 1	Levonorgestrel AUC decreased 64%; Cmax decreased 45%; Cmin decreased 71%; half-life: decreased 47%	Use alternative contraceptive method
Efavirenz G/P 450	Red: Avoid combination	Do not coadminister: Reduced levels of glecaprevir / pibrentasvir	Possible decrease in glecaprevir and pribrentasvir levels				contraindicated. Use alternative agents.
Efavirenz G/P 449	Red: Avoid combination	Do not coadminister: Reduced levels of glecaprevir / pibrentasvir	Possible decrease in glecaprevir and pribrentasvir levels				contraindicated. Use alternative agents.
Efavirenz ETR 448	Red: Avoid combination	Do not coadminister: Reduced levels of etravirine	Decreased etravirine and efavirenz effects			Etravirine AUC decreased 41%	Use alternative agents
Efavirenz EBR/GZR 447	Red: Avoid combination	Do not coadminister: Reduced levels of elbasvir / grazoprevir			Elbasvir 50 mg daily with grazoprevir 100 mg daily	Elbasvir AUC decreased 54% Grazoprevir AUC decreased 83%	Contraindicated. Use alternative agents.
Efavirenz EBR/GZR 446	Red: Avoid combination	Do not coadminister: Reduced levels of elbasvir / grazoprevir	decreased of elbasvir / grazoprevir effects				Contraindicated. Use alternative agents.
Efavirenz EBR/GZR 445	Red: Avoid combination	Do not coadminister: Reduced levels of elbasvir / grazoprevir	decreased of elbasvir / grazoprevir effects		Elbasvir 50 mg daily with grazoprevir 100 mg daily	Elbasvir AUC decreased 54% Grazoprevir AUC decreased 83%	Contraindicated. Use alternative agents.
Efavirenz Cariprazine 444	Red: Avoid combination	Do not coadminister: Reduced levels of cariprazine	Decreased cariprazine levels				Avoid combination and use alternative agents
Efavirenz CBZ 443	Red: Avoid combination	Do not coadminister: Reduced levels of carbamazepine and efavirenz	Decreased efavirenz and carbamazepine levels	Efavirenz AUC decreased 36%; Cmax decreased 21%; Cmin decreased 47%	200 mg daily on days 1-3, 200 mg BID on days 4-6, 400 mg daily thereafter	Carbamazepine AUC decreased 27%; Cmax decreased 20%; Cmin decreased 35%	Avoid combination and use alternative agents. If coadministering monitor carbamazepine levels and adjust as indicated. Monitor antiviral efficacy
Efavirenz Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide 442	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir / cobicistat	Potentially decreased or increased elvitegravir, cobicistat and / or efavirenz effects	Not studied (may decrease elvitegravir and cobicistat levels)		Not studied	Use alternative agents
Efavirenz St. John's Wort (Hypericum perforatum) 441	Red: Avoid combination	Do not coadminister: Potential for reduced levels of efavirenz	Decreased efavirenz effects	Not studied (may decrease efavirenz levels)		Not studied	Contraindicated. Use alternative agents.
Efavirenz ATV/c 440	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy	Not studied		Not studied (may decrease atazanavir and cobicistat levels)	Use alternative agents
Efavirenz ATV 439	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy		300 mg daily / ritonavir 100 mg daily days 1-10 then 400 mg daily / ritonavir 100 mg daily days 11-24	Atazanavir Cmin decreased 43%, Cmax increased 17%	Use alternative agents
Efavirenz ATV 438	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy		300 mg daily / ritonavir 100 mg daily days 1-10 then 400 mg daily / ritonavir 100 mg daily days 11-24	Atazanavir Cmin decreased 42%, Cmax increased 17%	Use alternative agents
Efavirenz ATV 437	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy		400 mg daily d 1-6, then 300 mg daily days 7_-20 with ritonavir 100 mg daily	Atazanavir auc increased 39%, Cmax increased 48%, Cmin increased 48%.	Use alternative agents
Efavirenz ATV 436	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy		400 mg daily d 1-6, then 300 mg daily days 7_-20 with ritonavir 100 mg daily	Atazanavir auc increased 39%, Cmax increased 48%, Cmin increased 14%.	Use alternative agents
Efavirenz ATV 435	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy		400 mg daily x 20 days	Atazanavir AUC decreased 74%, Cmax decreased 59%, Cmin decreased 93%.	Use alternative agents
Efavirenz ATV 434	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy		400 mg daily x 20 days	Atazanavir AUC decreased 74%, Cmax decreased 59%, Cmin decreased 93%.	Use alternative agents
Efavirenz Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 433	Red: Avoid combination	Do not coadminister: Potential for reduced antiviral activity	Significant GI and neurologic adverse events occurred, increase ALT	Not studied		Not studied (may decrease paritaprevir levels)	Contraindicated. Use alternative agents.
Efavirenz Ergotamine 432	Red: Avoid combination	Do not coadminister: Potential for increased levels of ergotamine	Potentially increased ergotamine effects (eg, ergotism)	Not studied		Not studied (may increase ergotamine levels)	Avoid combination and use alternative agents
Efavirenz RPT 431	Green: Administer standard doses	Administer standard doses		Efavirenz AUC decreased 14%; Cmin decreased 15%	900 mg Q week
Efavirenz Famotidine 430	Green: Administer standard doses	Administer standard doses		No significant change	40 mg x 1 dose
Efavirenz AZT, ZDV 429	Green: Administer standard doses	Administer standard doses		No significant change	300 mg Q12h x 14 days
Efavirenz Aluminum and magnesium hydroxide antacid 428	Green: Administer standard doses	Administer standard doses		No significant change	30 mL x 1 dose
Efavirenz SOF 427	Green: Administer standard doses	Administer standard doses			400 mg x 1	Sofosbuvir Cmax decreased 19%
Efavirenz Medroxyprogesterone acetate 426	Green: Administer standard doses	Administer standard doses		Efavirenz AUC no significant change	150 mg	Progesterone levels: no significant change
Efavirenz Valproic acid 425	Green: Administer standard doses	Administer standard doses		Efavirenz Cmin no significant change; Cmax no significant change; AUC no significant change; half-life: decreased 22%	250 mg BID x 7 days	No significant change
Efavirenz 3TC 424	Green: Administer standard doses	Administer standard doses		Not studied	150 mg Q12H x 14 days	No significant change
Efavirenz NFV 423	Green: Administer standard doses	Administer standard doses			750 mg TID	Nelfinavir clearance: no significant changeM8 clearance: increased 43%

Subscribe to Efavirenz